

# Matthew Mei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2926433/publications.pdf>

Version: 2024-02-01

85  
papers

1,840  
citations

331670

21  
h-index

289244

40  
g-index

86  
all docs

86  
docs citations

86  
times ranked

2694  
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
2	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. <i>Haematologica</i> , 2022, 107, 1214-1217.	3.5	5
3	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent lbrutinib. <i>Bone Marrow Transplantation</i> , 2022, 57, 830-833.	2.4	2
4	Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post Autologous Stem Cell Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	2
5	Autologous Stem Cell Transplantation in Hodgkin Lymphomaâ€”Latest Advances in the Era of Novel Therapies. <i>Cancers</i> , 2022, 14, 1738.	3.7	5
6	PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e893-e897.	0.4	2
7	Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 1-7.	2.3	9
8	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 2190-2199.	7.0	110
9	Rebound thrombocytosis is associated with response in <scp>AML</scp> patients treated with venetoclax and hypomethylating agents. <i>American Journal of Hematology</i> , 2021, 96, E140-E143.	4.1	1
10	Immune thrombocytopenia after immune checkpoint inhibitor therapy. <i>British Journal of Haematology</i> , 2021, 193, 677-681.	2.5	3
11	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 170-175.	0.4	17
12	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	1.2	6
13	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	7.0	23
14	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	6.2	2
15	Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices. <i>Cancer Treatment and Research</i> , 2021, 181, 45-55.	0.5	2
16	Current and Emerging Therapies for Acute Myeloid Leukemia. <i>Cancer Treatment and Research</i> , 2021, 181, 57-73.	0.5	2
17	Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 5300-5311.	5.2	9
18	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial). <i>Blood</i> , 2021, 138, 3847-3847.	1.4	7
20	Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. <i>Blood</i> , 2021, 138, 234-234.	1.4	5
21	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2021, 138, 2448-2448.	1.4	6
22	The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2021, 138, 417-417.	1.4	0
23	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955.	1.4	0
24	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13
25	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 877-883.	2.4	13
26	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	1.6	216
27	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327.	2.0	32
28	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 3532-3533.	1.3	5
29	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1425-1432.	2.0	5
30	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199.	4.1	28
31	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
32	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 1034-1044.	7.0	48
33	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	2.5	19
34	Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e320-e327.	0.4	5
35	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
36	VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 13-14.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	1.4	17
38	Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 41-43.	1.4	5
39	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. <i>Blood</i> , 2020, 136, 40-41.	1.4	2
40	Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. <i>American Journal of Hematology</i> , 2019, 94, 358-362.	4.1	46
41	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E253-E255.	4.1	62
42	Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e45-e48.	2.5	49
43	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2517-2521.	2.0	19
44	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.4	12
45	Pulmonary Arterial Hypertension (PAH) Is Associated with Increased Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation (allo HCT) for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S121.	2.0	0
46	MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. <i>Blood Advances</i> , 2019, 3, 83-95.	5.2	51
47	A Retrospective Study of Blinatumomab Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed and Refractory ALL. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S101-S102.	2.0	1
48	A Retrospective Study of Venetoclax-Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) in High-Risk Acute Myeloid Leukemia (AML) Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S102-S103.	2.0	3
49	Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e183-e185.	2.0	7
50	Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. <i>Blood Advances</i> , 2019, 3, 4043-4049.	5.2	55
51	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 287-292.	2.0	6
52	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. <i>Blood</i> , 2019, 133, 306-318.	1.4	26
53	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 239-239.	1.4	31
54	Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 759-759.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years. <i>Blood</i> , 2019, 134, 237-237.	1.4	19
56	Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning. <i>Blood</i> , 2019, 134, 669-669.	1.4	4
57	Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above. <i>Blood</i> , 2019, 134, 2852-2852.	1.4	0
58	Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. <i>Blood</i> , 2019, 134, 4623-4623.	1.4	0
59	Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. <i>Blood</i> , 2019, 134, 5729-5729.	1.4	1
60	Transplant Outcomes in Patients with AML Carrying IDH 1 and 2 Mutations: Retrospective Study From a Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S233.	2.0	1
61	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	4.1	61
62	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e404-e407.	3.5	212
63	How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 26-33.	0.4	5
64	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
65	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835.	2.0	15
66	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018, 103, 1662-1668.	3.5	41
67	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1636-1636.	1.4	5
68	Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 334-334.	1.4	6
69	Trends and Characteristics of Adult Acute Lymphoblastic Leukemia in a Public Safety-Net Hospital. <i>Blood</i> , 2018, 132, 5160-5160.	1.4	0
70	MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 1752-1752.	1.4	0
71	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386.	1.4	0
72	Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. <i>Value in Health</i> , 2017, 20, 200-205.	0.3	39

#	ARTICLE	IF	CITATIONS
73	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869.	2.0	19
74	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	1.6	152
75	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.9	15
76	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 738-738.	1.4	5
77	A Novel Method for Evaluating Value Assessment Frameworks. <i>Value in Health</i> , 2016, 19, A376.	0.3	1
78	Outcome of Patients with Recurrent or Refractory Lymphoma Undergoing Myeloablative Allogeneic HCT Using BEAM Conditioning with Tacrolimus/Sirolimus Based Gvhd Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S227.	2.0	0
79	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	1.4	3
80	Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody-Drug Conjugates: Focus on Brentuximab Vedotin. <i>BioDrugs</i> , 2014, 28, 245-251.	4.6	11
81	Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2072-2075.	2.0	15
82	The Role of Transplant in Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1131-1138.	4.9	1
83	Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 260-265.	2.0	42
84	Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2006, 99, 1377-1388.	3.9	28
85	p38 Activation Mediates Amyloid- $\beta^2$ Cytotoxicity. <i>Neurochemical Research</i> , 2005, 30, 791-796.	3.3	43